Literature DB >> 27346654

Prevalence and Medication Management of Dementia by a Medical Practice Providing Onsite Care in Assisted Living.

Alan Kronhaus1, Steven Fuller2, Sheryl Zimmerman3, David Reed4.   

Abstract

BACKGROUND/
OBJECTIVES: Assisted living (AL) is an important provider of long-term residential care to people with dementia, but little research has used clinician's records-arguably the most reliable and valid source of medically related information. This article uses clinician records to examine the prevalence of dementia, treatment with dementia-specific medications and antipsychotic medications, and how prescribing varies by assisted living residence (ALR) and resident characteristics.
DESIGN: Analysis of medical records from a long-term care medical practice.
SETTING: Ninety ALRs that had onsite care provided to some or all of their residents by one group practice that specializes in home-based primary care. PARTICIPANTS: Records for 3175 AL residents. MEASUREMENTS: Thirty-six variables related to the ALR, resident demographics, and medical conditions and pharmaceutical treatment.
RESULTS: Seventy-six percent of patients had a documented diagnosis of dementia, 41% who were treated with a medication for dementia other than an antipsychotic, and 37% who received an antipsychotic. Dementia medications were more likely to be prescribed to patients with dementia living in ALRs that had a memory care unit, and also to patients who were not Medicaid beneficiaries. Antipsychotic prescribing was similarly more common for residents with dementia living in ALRs that had memory care units.
CONCLUSION: The 76% prevalence rate of dementia in ALRs larger than 25 beds may be a more accurate reflection of the prevalence of dementia reported elsewhere, because it is based on diagnoses documented by patients' primary care clinicians. The reporting of treatment rates for dementia medications and antipsychotics, and how they vary in relation to ALR and resident characteristics, is meant to generate discussion about "best practices" and standards of care in the medication management of dementia and its behavioral comorbidities-topics that have received scant attention to date other than widespread attention to the need to reduce antipsychotic prescribing.
Copyright © 2016 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Assisted living; anti-psychotic; long-term care practice; medications; memory care

Mesh:

Substances:

Year:  2016        PMID: 27346654     DOI: 10.1016/j.jamda.2016.04.028

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  6 in total

1.  Polypharmacy in Assisted Living and Impact on Clinical Outcomes.

Authors:  Barbara Resnick; Elizabeth Galik; Marie Boltz; Sarah Holmes; Steven Fix; Erin Vigne; Shijun Zhu; Regina Lewis
Journal:  Consult Pharm       Date:  2018-06-01

2.  The Imperative to Reimagine Assisted Living.

Authors:  Sheryl Zimmerman; Paula Carder; Lindsay Schwartz; Johanna Silbersack; Helena Temkin-Greener; Kali S Thomas; Kimberly Ward; Robert Jenkens; Liz Jensen; Alfred C Johnson; Jed Johnson; Tim Johnston; Loretta Kaes; Paul Katz; Juliet Holt Klinger; Cathy Lieblich; Beth Mace; Kevin O'Neil; Douglas D Pace; Kezia Scales; Robyn I Stone; Sarah Thomas; Paul J Williams; Keren Brown Williams
Journal:  J Am Med Dir Assoc       Date:  2021-12-31       Impact factor: 4.669

3.  As-Needed Prescribing and Administration of Psychotropic Medications in Assisted Living: A 7-State Study.

Authors:  Paula Carder; Sheryl Zimmerman; Christopher J Wretman; John S Preisser; Sarah Dys; Philip D Sloane
Journal:  J Am Med Dir Assoc       Date:  2021-12-14       Impact factor: 7.802

4.  Prevalence of, and Resident and Facility Characteristics Associated With Antipsychotic Use in Assisted Living vs. Long-Term Care Facilities: A Cross-Sectional Analysis from Alberta, Canada.

Authors:  Kathryn J Stock; Joseph E Amuah; Kate L Lapane; David B Hogan; Colleen J Maxwell
Journal:  Drugs Aging       Date:  2017-01       Impact factor: 3.923

5.  Changes in the use of psychotropic drugs during the course of Alzheimer's disease: A large-scale longitudinal study of French medical records.

Authors:  Manon Ansart; Stéphane Epelbaum; Marion Houot; Thomas Nedelec; Béranger Lekens; Laurène Gantzer; Didier Dormont; Stanley Durrleman
Journal:  Alzheimers Dement (N Y)       Date:  2021-09-14

6.  Reimagining Medical Care in Assisted Living.

Authors:  Paul R Katz; Sarah Howd; Casey Rust
Journal:  J Am Med Dir Assoc       Date:  2022-02       Impact factor: 4.669

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.